Dec 30, 2019

FDA fumbled opioid safety program

Photo: Al Drago/CQ Roll Call via Getty Images

The FDA and opioid manufacturers failed to independently determine whether physician safety training and patient medication guides mitigated improper opioid prescriptions and misuse, according to new federal records obtained by researchers through the Freedom of Information Act.

Why it matters: Federal regulators created this safety program in 2012 because opioid addictions, overdoses and deaths were rising, but researchers say the FDA's program relied on poor designs and data collection — and ultimately did nothing to prevent the opioid crisis from getting worse.

Go deeper

AP: China's hidden, growing opioid crisis

Oxycodone, an addictive narcotic pain reliever. Photo: Education Images/Universal Images Group via Getty Images

A lack of treatment options, overprescription and little official understanding of the scale of painkiller abuse in China are likely contributing to the spread of opioid addiction in the country, per AP analyses.

What's happening: Drug company Mundipharma has "pushed ever larger doses" of painkillers like OxyContin in China, "even as it became clear that higher doses present higher risks," AP found in November. Mundipharma is owned by the Sackler family, which also owns Purdue Pharma, the OxyContin maker accused of helping fuel the U.S. opioid crisis.

Go deeperArrowDec 31, 2019

Opioid company founder gets 5.5-year prison sentence

Insys founder John Kapoor. Photo: Craig F. Walker/The Boston Globe via Getty Images

A judge has sentenced John Kapoor, the founder and former CEO of Insys Therapeutics, to 5.5 years in prison after a jury found him guilty in a bribery and racketeering scheme around the company's potent opioid drug, Subsys.

Why it matters: "Kapoor, 76, is now the highest-ranking pharmaceutical executive to be sentenced in a case linked to the opioid crisis," Reuters reports.

Keep ReadingArrowJan 23, 2020

AmerisourceBergen CEO earned $14.7 million in company stock gains in 2019

Steven Collis, CEO of drug distributor AmerisourceBergen, made $14.7 million in his company's 2019 fiscal year based on the actual realized gains on his stock, according to new company disclosures.

The big picture: That amount was down from the $18.7 million Collis earned in 2018.

Go deeperArrowJan 27, 2020